



ASX ANNOUNCEMENT

7 January 2019

## ***Cynata Therapeutics Receives Notice of Acceptance from IP Australia for Cymerus™ Patent Application***

**Melbourne, Australia; 7 January 2019:** Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, announced today that a Notice of Acceptance has been received from IP Australia for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology.

The patent application, entitled “Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions,” is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.

The Company has previously announced it has received a Notice of Allowance from the European Patent Office for a patent application and has been granted a patent in the United States by the US Patent and Trademark Office covering the same technology.

“Cynata’s robust intellectual property portfolio around the Cymerus therapeutic stem cell platform technology continues to expand and strengthen,” said Dr. Ross Macdonald, Cynata’s Chief Executive Officer. “This further patent reinforces our proprietary method of manufacturing MSCs which enables us to economically produce therapeutic MSCs at scale with consistent quality from a single blood donation. We look forward to the continued development of our patent estate as the Company also advances multiple Phase 2 clinical programs in multiple therapeutic areas of high unmet medical need during the course of 2019.”

The inventors named on the patent are Dr Gene Uenishi and Professor Igor Slukvin. Professor Slukvin is a founder, advisor and shareholder of Cynata.

The Notice of Acceptance is sent to the applicant when IP Australia (i.e. the Australian Government’s patent agency) intends to issue a patent. Cynata anticipates that the patent will be granted by late April 2019, with an expiration date of 12 March 2034.

**Ends**

**CONTACTS:** Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, [ross.macdonald@cynata.com](mailto:ross.macdonald@cynata.com)  
Rosa Smith, Australia Media Contact, +61 (0) 475 305 047, [rosa.smith@mcpartners.com.au](mailto:rosa.smith@mcpartners.com.au)  
Annie Starr, U.S. Media Contact, +1 973 768 2170, [astarr@6degreesspr.com](mailto:astarr@6degreesspr.com)

### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale and without the limitation of multiple donors.

**Cynata Therapeutics Limited**  
Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia  
PO Box 7165, Hawthorn North, Victoria 3122  
T: + 613 9824 5254 F: + 613 9822 7735 E: [admin@cynata.com](mailto:admin@cynata.com)  
ABN - 98 104 037 372



Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD and critical limb ischemia. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, critical limb ischemia, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.